Partnering
BD
Actively seeking collaboration with a broad range of global partners—including multinational pharma, innovative biotechs, venture capital funds, and regional leaders—we aim to drive efficient R&D transformation, rapidly expand into international markets through our partners' networks, accelerate our integration into the global innovation ecosystem, and maximize product value.
Strategic Alliance (MNCs)
2025
Granted global rights outside Greater China to GSK for up to 12 innovative drugs, including the PDE3/4 inhibitor HRS-9821.
NewCo(Top-tier PE/VCs)
2024
Granted global rights outside Greater China to US-based Kailera Therapeutics (backed by Bain Capital, etc.) for the GLP-1 portfolio (HRS-7535, HRS9531, HRS-4729). Kailera went public on NASDAQ in April 2026.
2025
Granted global rights outside Greater China to US-based Braveheart Bio (backed by Forbion, OrbiMed, etc.) for the myosin inhibitor HRS-1893.
Out-licensing (Leading MNC/Biotechs)
2023
Granted global rights outside Greater China to US-based Treeline Biosciences for the EZH2 inhibitor SHR2554.
Granted global rights outside Greater China to US-based Aiolos Bio for the anti-TSLP monoclonal antibody SHR-1905. Aiolos Bio was later acquired by GSK.
Granted rights within India to India-listed Dr. Reddy's for the TKI pyrotinib.
Granted rights outside Greater China and South Korea to US-based Elevar Therapeutics for the PD-1 inhibitor camrelizumab combination therapy for the treatment of hepatocellular carcinoma.
2024
Granted global rights outside Greater China to US-based IDEAYA Biosciences for the DLL3-targeted ADC SHR-4849.
2025
Granted global rights outside Greater China to MSD for the Lp(a) inhibitor HRS-5346.
Granted rights within Mainland China to Merck KGaA for the oral GnRH antagonist SHR-7280.
Granted rights in select international markets, excluding Greater China, the US, Europe, and Japan, to India-based Glenmark Pharmaceuticals for the HER2 ADC Trastuzumab Rezetecan.